Fate Therapeutics (FATE) Tops Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ACCV
4. AZN
5. FICO
6. GMAB
7. QQQ
8. SPCX
9. APO
10. SMMT

Go back to Fate Therapeutics (FATE) Tops Q3 EPS by 6c

Fate Therapeutics Reports Third Quarter 2015 Financial Results

November 3, 2015 4:02 PM EST

Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting

First-in-Human Clinical Trial of PROTMUNE to Prevent Acute GvHD and Severe Infections Planned for 2016

Reached 70% of Target Enrollment for PROHEMA® PUMA Study

SAN DIEGO, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2015.

"We have... More